THE EFFECTIVENESS OF DIRECT ANTIVIRAL MEDICATIONS IN HCV-POSITIVE PATIENTS IN PROGRAM HEMODIALYSIS AND TRANSPLANT WAITING LIST

Р.Н. АКАЛАЕВ, Ф.А. АРИПХОДЖАЕВА, С.А. РАШИДОВА, А.Н. АБДУЛЛАЕВ, Н.С. РАХИМОВА, Г.З. АРИПХОДЖАЕВА, В.Х. ШАРИПОВА, А.А. СТОПНИЦКИЙ

Abstract

Objective. To study the effectiveness, tolerance and safety of direct antiviral medications in HCV-positive patients with end stage renal diseases (ESRD) who are chronic kidney replacement therapy.Material and methods. HCV-positive 125 patients with 1 to 7 years history of program hemodialysis were examined. Patients’ age was 43,5±0,91. 33% of them (41) were women and 67% (84) were men. We provide antiviral therapy to 28 HCV-positive patients of department of hemodialysis using direct-acting drug VIRPAS (ledipasvir 90 mg + sofosbuvir 400 mg).Results. HCV-positive patients with ESRD more frequently (р<0,05) manifest with intoxication symptoms. In this patients we also revealed significantly (р<0,05) higher incidence of anemia and polyserositis such as ascites, pericarditis, hydrothorax. During the direct-acting antiviral therapy the level of RNA-HCV was not detected at the 4th week in 42,8% of patients. At the end of 12-week follow-up, in 92,5% patients RNA-HCV results were negative.Summary. Ledipasvir + Sofosbuvir based direct-acting antiviral therapy demonstrated its satisfactory tolerance, safety and effectiveness for using in ESRD patients with chronic viral hepatitis C, which allows us to recommend this drug for patients of this category.Key words: viral hepatitis C, end stage renal disease, antiviral therapy.